UFHCC Pilot Project Awards
SPECIAL CALL: Prostate, Kidney, and Bladder Cancer Research Pilot
DUE: Monday, January 25, 2021
CANCER POPULATION SCIENCES RESEARCH PROGRAM PILOT
DUE: Monday, January 25, 2021
UFHCC Pilot Templates
This UFHCC Cancer-Focused A1 Accelerator Grant Program is designed to support promising new research or competitive renewals that have nearly missed funding pay lines. The research must have strong cancer relevance; clinical, basic and population research grants are all acceptable.
For NCI and other cancer-focused NIH proposals, applications that have been scored or ranked within 5% of the Institute’s published funding pay line will receive automatic bridge funding from the cancer center. Full-time UFHCC faculty members in Gainesville may apply. Newly recruited Assistant Professors are eligible to apply, whereas newly recruited senior faculty with start-up packages from the cancer center are not eligible.
Award Amount and Duration
- The maximum award for these grants is $75,000 direct cost for R01s and $50,000 for R21s. No IDC is allowed.
- The award is for a period of one year and all funds are expected to be expended during that term.
Applications will be accepted on a rolling basis. Applicants should submit their full Federal proposal with a screenshot of their score/percentile to ResearchAdmin@cancer.ufl.edu.
Early Stage & Early Established Investigators
Early Stage Investigators whose applications scored outside of the 5th percentile range will be considered on an individual basis.
The goals of the UFHCC’s Pilot Project Program are to:
- Provide developmental support for promising, cancer-focused collaborative research projects with a well-defined major objective or theme;
- Create synergies and lasting collaborations between cancer researchers that will lead to impactful publications and stimulate collaborative grant applications for future Federal or other peer-reviewed extramural cancer research funding.
- UFHCC Allowable/Non-Allowable Costs
Triple Negative Breast Cancer (TNBC) – defined as estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 (HER2) negativity – is heterogeneous with respect to biology, prognosis and response to treatment. TNBC can be associated with BRCA1 & BRCA2 mutations and is associated with younger age at diagnosis and with poorer outcomes compared with non-TNBC. Studies are needed to improve our understanding of its biology and current management and outcome of patients diagnosed with TNBC.
This funding opportunity has been made available through generous philanthropic support to the UF Health Cancer Center. It recognizes that i) the study of TNBC is underrepresented in academic and industry research portfolios, and ii) there exists a great need to advance our understanding of the genetics and biology of TNBC and for implementing new strategies for clinical trials.
- Identify new research opportunities focused on the biology or treatment of TNBC;
- Create synergies and collaborations among UF Health Cancer Center members and other members of University of Florida, Gainesville;
- Stimulate applications for future program-type federal or national extramural funding.
An initiative of the Florida Academic Cancer Center Alliance, the intent of this grant mechanism is to foster new collaborative projects involving the Moffitt Cancer Center, the University of Florida Health Cancer Center and the University of Miami Sylvester Comprehensive Cancer Center. This opportunity is designed to further build collaboration amongst the three centers, each of which is providing funding for the awards. Each proposal requires strong, meaningful collaboration by investigators from at least two of the three centers.